{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-045266","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2024-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.830373+00:00","generated_at":"2026-06-04T00:55:22.697535+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Verastem outlines NDA filing plan for avutometinib/defactinib in LGSOC by H1 2024; cash $137.1M","bullets":["Topline data from RAMP 201 trial of avutometinib + defactinib in LGSOC expected H1 2024; rolling NDA for accelerated approval to commence same period.","Confirmed ORR of 45% with tumor shrinkage in 86% of evaluable patients from RAMP 201 Part A (June 2023 data).","GenFleet partnership: IND for oral KRAS G12D inhibitor GFH375/VS-7375 expected in China H1 2024; Phase 1 initiation H2 2024.","Initial safety/efficacy data from RAMP 205 (avutometinib + gemcitabine/nab-paclitaxel + defactinib) in front-line metastatic pancreatic cancer due H1 2024.","Ended Q4 2023 with $137.1M cash; GAAP operating expenses $31.14M ($29.54M non-GAAP) in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-045266","json":"https://secwatch.observer/filing/0001104659-24-045266.json","markdown":"https://secwatch.observer/filing/0001104659-24-045266.md","text":"https://secwatch.observer/filing/0001104659-24-045266.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465924045266/0001104659-24-045266-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465924045266/tm2411327d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:55:22.697535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}